You are here: Industry Insights > Fulcrum

News List

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares firstwordpharma
August 17, 2021
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced closing of its previously announced underwritten public offering of 7,590,000 shares of its common stock at a public offering price of $19.00 per share
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock firstwordpharma
August 11, 2021
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the shares are being offered by Fulcrum.
Fulcrum Therapeutics Announces CEO Transition americanpharmaceuticalreview
March 09, 2021
Fulcrum Therapeutics announced Bryan E. Stuart, the company’s chief operating officer, will become Fulcrum’s president and chief executive officer and will be appointed to the Board of Directors. Stuart will succeed current president and ...
Fulcrum to Initiate FTX-6058 Trial for Sickle Cell Disease americanpharmaceuticalreview
October 12, 2020
Fulcrum Therapeutics announced the Investigational New Drug application (IND) is now in effect for its Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease.
Fulcrum to Evaluate Losmapimod as Potential COVID-19 Treatment americanpharmaceuticalreview
June 19, 2020
Fulcrum Therapeutics has announced plans to evaluate losmapimod as a potential treatment for patients with COVID-19.
Fulcrum acquires global rights of investigational drug losmapimod from GSK pharmaceutical-business-review
April 24, 2019
Fulcrum Therapeutics has acquired all worldwide development and commercialization rights of investigational drug losmapimod from GlaxoSmithKline (GSK).